$ADVB

Biotech gainers highlighted include Advanced Biomed (ADVB), up about 211% this week to $16.78, with no product sales and a recent SEC registration withdrawal. Novocure (NVCR) rose over 28% after Q2 results and raised 2026 revenue guidance to $710M-$725M. Medpace (MEDP) gained 14% on Q2 revenue of $707.3M and 2026 outlook. SciSparc (SPRC) and Agenus (AGEN) also rose; AgomAb (AGMB) gained on upcoming trial readouts.

Biotech stocks hit 52-week highs on July 22, 2026. Advanced Biomed (ADVB) jumped over 73% to $18.73. BioLife Solutions (BLFS) rose over 6% to $31.49 after Repligen (RGEN) agreed to acquire it for about $1.5B. Forte Biosciences (FBRX) rose over 11% to $56.84. Silence Therapeutics (SLN) rose over 9% to $11.90. LB Pharmaceuticals (LBRX) rose over 10% to $36.59.

Biotech gainers included Zhengye Biotechnology (ZYBT), up about 1,048% after a Nasdaq bid-price noncompliance notice. Advanced Biomed (ADVB) rose over 70% after withdrawing a planned SEC-registered offering. Neuronetics (STIM) gained after naming a new CFO. Armata Pharmaceuticals (ARMP) advanced on Phase 3 AP-SA02 progress. Other movers: Profusa (PFSA), Ridgetech (RDGT), Turn Therapeutics (TTRX).

Advanced Biomed Inc. (ADVB) filed an SEC Form 8-K — Termination of a Material Definitive Agreement. false 00000 0001941029 0001941029 2026-07-14 2026-07-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 July 14

Advanced Biomed Inc. (ADVB) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 00000 0001941029 0001941029 2026-06-30 2026-06-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 June 30

Advanced Biomed Inc. (ADVB) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 ea029652901ex10-1.htm SHARE PURCHASE AGREEMENT, DATED AS OF JUNE 30, 2026 Exhibit 10.1 SHARE PURCHASE AGREEMENT This Share Purchase Agreement (this “ Agreement ”), dated as of June 30, 2026, is entered into by and among Advanced Biomed Inc., a Nevada corporation (“ Sell

Advanced Biomed Inc. (ADVB) is a biotechnology company specializing in diagnostics and research for cancer and precision medicine, utilizing microfluidic biochip technologies and 3D cell culture platforms. The company recently completed a 1-for-20 reverse stock split and sold its Hong Kong subsidiary as part of a strategic realignment. ADVB's stock price currently stands at $4.15 with a market capitalization of $5.7M, and it has faced Nasdaq listing compliance issues regarding minimum bid price.

Advanced Biomed (ADVB) has entered into a Supplemental Agreement with Wei Ha Hui concerning the spin-off of Advanced Biomed (HK). The agreement formalizes the repayment of $6,925,549 that Advanced Biomed (HK) owes the company, with the full amount to be repaid within one year. This amendment, approved by the board, adds the repayment obligation to the existing spin-off terms to ensure an orderly separation and recovery of intercompany receivables.

[Tainan City], Taiwan, Sept. 19, 2025 ( GLOBE NEWSWIRE ) -- Advanced Biomed Inc. ( Nasdaq: ADVB ) ( the "Company", "Advanced Biomed" ) , a biotechnology company focused on developing and commercializing innovative biomedical products for precision medicine and advanced diagnostics, today ...